# A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell Carcinoma

> **NCT05783921** · PHASE1,PHASE2 · UNKNOWN · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 60 (estimated)

## Conditions studied

- Recurrent Squamous Cell Carcinoma of the Head and Neck
- Metastatic Squamous Cell Carcinoma

## Interventions

- **DRUG:** TQB2618 injection, Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin
- **DRUG:** Penpulimab injection, Paclitaxel, Cisplatin or Carboplatin

## Key facts

- **NCT ID:** NCT05783921
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-05-23
- **Primary completion:** 2024-08
- **Final completion:** 2025-01
- **Target enrollment:** 60 (ESTIMATED)
- **Last updated:** 2023-07-28


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05783921

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05783921, "A Clinical Trial of TQB2618 Injection Combined With Penpulimab Injection and Chemotherapy Versus Penpulimab Injection Combined With Chemotherapy in First-line Treatment of Relapsed/Metastatic Head and Neck Squamous Cell Carcinoma". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT05783921. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*